Skip to main content

Table 1 Univariate survival analysis

From: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

  

Univariate

Covariate

Baseline

Coefficient

HR

95,0% CI for HR

p-value

Grade 2

Grade 1

2.047

7.742

(1.012-59.228)

0.049

Grade 3

Grade 1

2.955

19.193

(2.455-150.003)

0.005

T3

T2

-0.18

0.982

(0.128-7.517)

0.986

T4

T2

0.569

1.767

(0.228-13.717)

0.586

N1

N0

0.696

2.007

(0.696-5.783)

0.197

N2

N0

0.759

2.136

(0.714-6.383)

0.174

M

M0

0.606

1.833

(0.683-4.918)

0.229

Stage 3

Stage2

0.852

2.344

(0.686-8.008)

0.174

Stage 4

Stage2

1.088

2.970

(0.708-12.463)

0.137

ER

ER positive

1.335

3.800

(1.566-9.223)

0.003

PR

PR positive

0.620

1.859

(0.800-4.318

0.149

ErbB2

ErbB2 positive

0.965

2.624

(0.931-7.395)

0.068

TP53

Wild type TP53

1.230

3.423

(1.553-7.542)

0.002

ABCB1 _2

ABCB1 _2 Methylated

1.147

3.147

(1.389-7.133)

0.006

FOXC1 _3

FOXC1 _3 Methylated

1.030

2.802

(1.127-6.969)

0.027

GSTP1 _2

GSTP1 _2 Methylated

1.215

3.369

(1.280-8.868)

0.014

  1. Univariate survival analysis using the Cox regression model using the categorical methylation data. Positive hazard ratios indicate an increased risk of dying from breast cancer and are calculated for the different covariates in reference to the baseline as given in the 2nd column.
Back to article page

Molecular Cancer

ISSN: 1476-4598